budesonide

Summary

Summary: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.

Top Publications

  1. ncbi A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
    Jeffrey Weber
    Moffitt Cancer Center, Tampa, Florida 33612, USA
    Clin Cancer Res 15:5591-8. 2009
  2. ncbi Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease
    Tobias Welte
    Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    Am J Respir Crit Care Med 180:741-50. 2009
  3. pmc Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide
    M M Kelly
    Airways Inflammation Research Group, Institute of Infection, Immunity and Inflammation, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
    Br J Pharmacol 165:1737-47. 2012
  4. pmc Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial
    Stephen I Rennard
    Pulmonary Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 5885, USA
    Drugs 69:549-65. 2009
  5. ncbi Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency depart
    Lucie Blais
    University of Montreal, Quebec, Canada
    Clin Ther 32:1320-8. 2010
  6. ncbi Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials
    D M G Halpin
    Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, UK
    Int J Clin Pract 65:764-74. 2011
  7. ncbi Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study
    K Larsson
    Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 273:584-94. 2013
  8. pmc Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Int J Chron Obstruct Pulmon Dis 7:415-20. 2012
  9. ncbi The role of nebulised budesonide in the treatment of exacerbations of COPD
    H Gunen
    Dept of Pulmonary Medicine, Turgut Ozal Research Centre, Inonu University, Malatya 44069, Turkey
    Eur Respir J 29:660-7. 2007
  10. ncbi Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study
    Amir Sharafkhaneh
    Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine and Michael E DeBakey VA Medical Center Bldg 100 111i, Houston, TX 77030, USA
    Respir Med 106:257-68. 2012

Detail Information

Publications332 found, 100 shown here

  1. ncbi A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
    Jeffrey Weber
    Moffitt Cancer Center, Tampa, Florida 33612, USA
    Clin Cancer Res 15:5591-8. 2009
    ..placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylactic budesonide (Entocort EC), a nonabsorbed oral steroid, reduced the rate of grade >or=2 diarrhea in ipilimumab-treated ..
  2. ncbi Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease
    Tobias Welte
    Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    Am J Respir Crit Care Med 180:741-50. 2009
    b>Budesonide/formoterol and tiotropium are commonly used maintenance treatments for patients with chronic obstructive pulmonary disease. Combining these medications may provide additional benefits.
  3. pmc Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide
    M M Kelly
    Airways Inflammation Research Group, Institute of Infection, Immunity and Inflammation, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
    Br J Pharmacol 165:1737-47. 2012
    ..As there are no data to support this effect in asthmatic subjects taking ICS, we have assessed whether ICS induce anti-inflammatory gene expression in subjects with atopic asthma...
  4. pmc Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial
    Stephen I Rennard
    Pulmonary Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 5885, USA
    Drugs 69:549-65. 2009
    ..The efficacy and tolerability of the combination of budesonide/formoterol have been demonstrated in patients with COPD when administered via the dry powder inhaler (DPI) in a ..
  5. ncbi Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency depart
    Lucie Blais
    University of Montreal, Quebec, Canada
    Clin Ther 32:1320-8. 2010
    ..The relative effectiveness of combination products such as budesonide/formoterol (BUD/FM) and fluticasone propionate/salmeterol (FP/SM) has not been well documented.
  6. ncbi Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials
    D M G Halpin
    Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, UK
    Int J Clin Pract 65:764-74. 2011
    This analysis was designed to provide a comparison between budesonide/formoterol and salmeterol/fluticasone for the relative incidence of pneumonia adverse events, pneumonia serious adverse events and pneumonia-related mortality in ..
  7. ncbi Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study
    K Larsson
    Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 273:584-94. 2013
    ..The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol.
  8. pmc Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Int J Chron Obstruct Pulmon Dis 7:415-20. 2012
    ..in order to compare the efficacy of indacaterol 75 μg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic ..
  9. ncbi The role of nebulised budesonide in the treatment of exacerbations of COPD
    H Gunen
    Dept of Pulmonary Medicine, Turgut Ozal Research Centre, Inonu University, Malatya 44069, Turkey
    Eur Respir J 29:660-7. 2007
    The present study was designed to evaluate the hypothesis that nebulised budesonide (NB) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (..
  10. ncbi Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study
    Amir Sharafkhaneh
    Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine and Michael E DeBakey VA Medical Center Bldg 100 111i, Houston, TX 77030, USA
    Respir Med 106:257-68. 2012
    ..This randomized, double-blind, double-dummy, parallel-group, 12-month multicenter study evaluated the effect of budesonide/formoterol pressurized metered-dose inhaler (pMDI) on COPD exacerbations.
  11. ncbi Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide
    Lyndon E Mansfield
    Western Sky Medical Research, El Paso, Texas 79902, USA
    Ann Allergy Asthma Immunol 92:240-4. 2004
    ..Daytime sleepiness is a common finding in symptomatic allergic rhinitis. Effective therapy of the nasal congestion of allergic rhinitis should alter sleep patterns in patients with symptomatic allergic rhinitis...
  12. pmc The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
    Chris Dalby
    Respiratory Medicine Unit, City Hospital Campus, Nottingham University, Nottingham, UK
    Respir Res 10:104. 2009
    ..This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic ..
  13. ncbi Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD
    Bartolome R Celli
    Harvard University, Brigham and Women s Hospital, Pulmonary and Critical Care Medicine, Boston, MA 02115, USA
    Respir Med 105:1176-88. 2011
    ..We also evaluated the speed of onset of bronchodilation...
  14. pmc Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
    Luis Javier Nannini
    Pulmonary Section, Hospital E Peron, G Baigorria, Argentina
    Cochrane Database Syst Rev 9:CD006829. 2012
    ..This updated review compared compound LABA plus ICS therapy (LABA/ICS) with the LABA component drug given alone...
  15. ncbi Apoptosis of airway epithelial cells induced by corticosteroids
    D R Dorscheid
    McDonald Research Laboratories, the iCAPTURE Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Am J Respir Crit Care Med 164:1939-47. 2001
    ..Treatment with dexamethasone, beclomethasone, budesonide, or triamcinolone each elicited a time-dependent and concentration-dependent cell death...
  16. ncbi Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial
    Francois Maltais
    Centre de Recherche, Hopital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l Universite Laval, 2275 Chemin Ste Foy, Ste Foy, Quebec G1V 4G5, Canada
    Am J Respir Crit Care Med 165:698-703. 2002
    Nebulized budesonide has been used successfully to treat acute asthma exacerbation, and we hypothesized that it could also be effective for exacerbations of chronic obstructive pulmonary disease (COPD)...
  17. pmc Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis
    Shannon Cope
    Mapi Values, Boston, MA, USA
    Int J Chron Obstruct Pulmon Dis 6:329-44. 2011
    To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the ..
  18. ncbi Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection
    K Grunberg
    Department of Pulmonology, Department of Medical Decision Making, Leiden University Medical Center LUMC, Leiden, The Netherlands
    Am J Respir Crit Care Med 164:1816-22. 2001
    ..16 (RV16) infection, while receiving double-blind, placebo-controlled treatment with the inhaled corticosteroid budesonide (800 microg twice a day) throughout the study period, starting 2 wk before infection...
  19. ncbi Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
    Don D Sin
    Providence Heart and Lung Institute, St Paul s Hospital iCAPTURE Centre, and Department of Medicine Division of Respirology, University of British Columbia, Vancouver, BC, Canada
    Lancet 374:712-9. 2009
    ..We aimed to establish the effects of inhaled budesonide on the risk of pneumonia in such patients.
  20. ncbi Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
    I S T Bos
    Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Eur Respir J 30:653-61. 2007
    ..other aspects of airway remodelling and to compare the effectiveness of tiotropium to the glucocorticosteroid budesonide. Ovalbumin-sensitised guinea pigs were challenged for 12 weeks with aerosolised ovalbumin...
  21. ncbi Scientific rationale for using a single inhaler for asthma control
    P J Barnes
    Section of Airway Disease, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Eur Respir J 29:587-95. 2007
    Clinical trials have recently demonstrated that using a budesonide/formoterol combination inhaler as regular maintenance treatment twice daily but also as a rescue therapy for breakthrough symptoms can provide more effective control of ..
  22. ncbi Sensitivity of a new grading system for studying nasal polyps with the potential to detect early changes in polyp size after treatment with a topical corticosteroid (budesonide)
    L Johansson
    Department of Otorhinolaryngology, Central Hospital, Skovde, Sweden
    Acta Otolaryngol 122:49-53. 2002
    ..with bilateral nasal polyposis (n = 100) were randomized to a 2-week treatment with a topical corticosteroid (budesonide aqueous nasal spray: 128 microg b.i.d.) or placebo in a double-blind manner...
  23. ncbi Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials
    S J Edwards
    Outcomes Research, AstraZeneca UK Ltd, Luton, UK
    Int J Clin Pract 64:619-27. 2010
    To compare the effectiveness of budesonide/formoterol (Symbicort) for Maintenance and Reliever Therapy (Symbicort SMART) Turbuhaler with twice daily inhaled corticosteroid (ICS) treatment, alone or in combination with a long-acting beta(2)..
  24. ncbi Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 97:453-7. 2003
    ..the combination therapy with 50 microg salmeterol + 250 microg fluticasone and 12 microg formoterol + 400 microg budesonide, both in a single inhaler device, in 16 patients with moderate-to-severe COPD...
  25. ncbi Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma
    Margaret M Kelly
    Firestone Institute for Respiratory Health, Department of Medicine, St Joseph s Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario L8N 3Z5, Canada
    J Allergy Clin Immunol 125:349-356.e13. 2010
    ..However, there are limited data as to whether these beneficial effects are due to enhanced anti-inflammatory actions or whether such combination therapies affect airway remodeling in patients with asthma...
  26. ncbi Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol
    Lucie Blais
    Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, Canada
    Respir Med 103:237-43. 2009
    ..Whether the differences between budesonide/formoterol and fluticasone/salmeterol translate into differences in treatment outcomes in a real life setting is ..
  27. ncbi Intranasal budesonide treatment for children with mild obstructive sleep apnea syndrome
    Leila Kheirandish-Gozal
    Department of Pediatrics, Division of Pediatric Sleep Medicine, University of Louisville, Louisville, KY 40202, USA
    Pediatrics 122:e149-55. 2008
    ....
  28. ncbi A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
    J C Kips
    Department of Respiratory Diseases, University Hospital Ghent, Ghent, Belgium
    Am J Respir Crit Care Med 161:996-1001. 2000
    ..In a double-blind parallel-group study, we evaluated the effect of adding formoterol to a low dose of budesonide, compared with a higher dose of budesonide, on the composition of induced sputum...
  29. ncbi Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates
    Raoul Poupon
    UPMC Univ Paris 06, INSERM, UMR_S 938, Service d Hépatologie et Centre de Référence des Maladies Inflammatoires des Voies Biliaires, Hopital Saint Antoine, AP HP, Paris, France
    Dig Dis 29:85-8. 2011
    ..the following issues: the appropriate selection of patients requiring new therapeutic options, the role of budesonide in the management of these patients, and the emerging place of peroxisome proliferator-activated receptor-α ..
  30. ncbi Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease
    Nanshan Zhong
    State Key Lab of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China
    Curr Med Res Opin 28:257-65. 2012
    To evaluate the efficacy and safety of budesonide (BUD)/formoterol (FORM) compared with BUD, both administered by way of a dry powder inhaler (Turbuhaler * ). * Turbuhaler is a registered trade name of AstraZeneca, Södertälje, Sweden.
  31. ncbi The effects of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marrow eosinophilia, and eosinophil progenitor expansion in sensitized mice
    Huahao Shen
    Asthma Research Group, Department of Medicine, McMaster University and St Joseph s Hospital, Hamilton, Ontario, Canada
    Am J Respir Crit Care Med 166:146-53. 2002
    ..marrow eosinophil progenitors in sensitized mice and subjects with asthma and that the inhaled corticosteroid, budesonide, reduced baseline but not allergen-induced increase in bone marrow eosinophil/basophil progenitors (EoB-CFU) in ..
  32. ncbi The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation
    B H J Dickhoff
    Department of Pharmaceutical Technology and Biopharmacy, Groningen University Institute for Drug Exploration GUIDE, Groningen, The Netherlands
    Eur J Pharm Biopharm 54:245-8. 2002
    ..The decrease in residual drug on carrier is in agreement with increasing FPFs in an Erweka impactor. However, it has been calculated that the magnitude of the effect decreases with increasing de-agglomeration efficiency...
  33. ncbi Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages
    A Ek
    Department of Occupational Medicine, National Institute for Working Life, Solna, Sweden
    Allergy 54:691-9. 1999
    ..alveolar macrophages were stimulated with swine dust or lipopolysaccharide (LPS), and the inhibitory effect of budesonide and fluticasone propionate on cytokine release was studied in a dose-response (10(-13)-10(-8) M) manner...
  34. ncbi Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis
    Miguel Angel Martínez-García
    Pneumology Unit, La Fe University and Polytechnic Hospital, Av Bulevar Sur s n, 46026, Valencia, Spain
    Chest 141:461-8. 2012
    The aim of this study is to evaluate the efficacy and safety of medium-dose formoterol-budesonide combined inhaled treatment in a single inhaler compared with high-dose budesonide treatment in patients with non-cystic fibrosis (non-CF) ..
  35. ncbi Intrasinus administration of topical budesonide to allergic patients with chronic rhinosinusitis following surgery
    Francois Lavigne
    Centre Hospitalier Universitaire de Montréal Hôspital Nôtre Dame, McGill University Montreal, Quebec, Canada
    Laryngoscope 112:858-64. 2002
    Whether instillation into the maxillary sinus of topical budesonide affected the immune response and improved allergic patients with chronic rhinosinusitis that had persistence of symptoms despite appropriate surgical intervention was ..
  36. ncbi Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol
    Koichi Suda
    Division of Respiratory Medicine, University of British Columbia, Providence Heart and Lung Institute, St Paul s Hospital, 1081 Burrard St, Vancouver, British Columbia V6Z 1Y6, Canada
    Am J Respir Cell Mol Biol 45:510-6. 2011
    ..We sought to determine whether IL-6 contributes to the cardiovascular dysfunction related to ALI, and whether budesonide/formoterol ameliorates this process...
  37. ncbi Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Gastroenterology 139:1198-206. 2010
    ..Corticosteroid therapy induces long-term remission but has many side effects. We compared the effects of budesonide (a steroid that is rapidly metabolized, with low systemic exposure) and prednisone, both in combination with ..
  38. ncbi Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children
    Seema S Aceves
    Division of Allergy and Immunology, Children s Hospital, San Diego, La Jolla, California, USA
    Am J Gastroenterol 102:2271-9; quiz 2280. 2007
    ..Eosinophilic esophagitis (EE) is a disorder characterized typically by pan-esophageal eosinophilia. We evaluate a palatable, long-acting topical corticosteroid preparation for the treatment of EE...
  39. ncbi Combination of budesonide and aminophylline diminished acute lung injury in animal model of meconium aspiration syndrome
    D Mokra
    Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia
    J Physiol Pharmacol 59:461-71. 2008
    Combination of low-dose budesonide and low-dose aminophylline may improve lung function in reduced adverse effects compared with high-dose monotherapy. Adult rabbits intratracheally received 4 ml/kg of saline or meconium (25 mg/ml)...
  40. ncbi Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial
    Ranjan Dohil
    Departments of Pediatrics and Pathology, University of California, San Diego, La Jolla, California and Rady Children s Hospital San Diego, San Diego, California 92103 8450, USA
    Gastroenterology 139:418-29. 2010
    ..Placebo-controlled studies have not been conducted to evaluate the safety and efficacy of oral viscous budesonide (OVB).
  41. ncbi Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps
    R Jankowski
    Department of Otorhinolaryngology, Head and Neck Surgery, Central Hospital, , F-54000 Nancy, France
    Arch Otolaryngol Head Neck Surg 127:447-52. 2001
    OBJECTIVE: To assess the efficacy and tolerability of once-daily treatment with budesonide aqueous nasal spray in patients with nasal polyps. DESIGN: Randomized, double-blind, placebo-controlled, parallel-group study...
  42. ncbi Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study
    Tsu F Yeh
    Department of Pediatrics, College of Medicine, China Medical University, 91 Hsieh Shih St, Taichung, Taiwan
    Pediatrics 121:e1310-8. 2008
    b>Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects; it has been effectively delivered to animal lungs using surfactant as a vehicle...
  43. pmc Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?
    Milind P Sovani
    Division of Respiratory Medicine, University of Nottingham, Nottingham City Hospital
    Br J Gen Pract 58:37-43. 2008
    ..Poor adherence with inhaled corticosteroids is an important problem in asthma management. Previous approaches to improving adherence have had limited success...
  44. ncbi Localized eosinophilic ileitis with mastocytosis successfully treated with oral budesonide
    C Lombardi
    Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa, Italy
    Allergy 62:1343-5. 2007
  45. ncbi Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol
    Lizbet Todorova
    Department of Cell and Molecular Biology, Lund University, Lund, Sweden
    Am J Respir Cell Mol Biol 34:92-100. 2006
    Proteoglycans contribute to extracellular matrix remodeling in asthmatic airways. We investigated the effects of budesonide, a glucocorticoid, and formoterol, a long-acting beta2-adrenergic agonist, on serum-induced proteoglycan ..
  46. ncbi Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD
    Heinrich Worth
    Medical Department I, Fürth Hospital, Fürth, Germany
    Respir Med 104:1450-9. 2010
    ..Breathlessness and exercise intolerance frequently impact the daily life of patients with COPD...
  47. ncbi Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
    A Papi
    Research Centre on Asthma and COPD, University of Ferrara, Italy
    Eur Respir J 29:682-9. 2007
    ..Modulite (Chiesi Farmaceutici, Parma, Italy) pressurised metered-dose inhaler (pMDI), with a combination of budesonide and formoterol administered via a Turbuhaler (AstraZeneca, Lund, Sweden) dry powder inhaler (DPI)...
  48. ncbi Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD
    Martyn R Partridge
    Faculty of Medicine, Imperial College London, NHLI Division at Charing Cross Hospital, London, UK
    Ther Adv Respir Dis 3:1-11. 2009
    ..This is the first study to compare the effect of budesonide/formoterol and salmeterol/fluticasone on lung function, symptoms and activities early in the morning.
  49. pmc Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung
    Alberto Izzotti
    Department of Health Sciences, University of Genoa, Via A Pastore 1, I 16132 Genoa, Italy
    Carcinogenesis 31:894-901. 2010
    ..Thereafter, groups of mice received daily either budesonide (BUD) or phenethyl isothiocyanate (PEITC) with the diet...
  50. ncbi Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial
    Henna Rautiainen
    Department of Medicine, Division of Gastroenterology, Helsinki University Central Hospital, 00029 HYKS, Finland
    Hepatology 41:747-52. 2005
    ..b>Budesonide is a glucocorticoid with high receptor activity and high first-pass metabolism in liver...
  51. pmc Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
    D B Price
    Department of General Practice and Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen AB25 2AY, Scotland, UK
    Thorax 58:211-6. 2003
    ..This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma.
  52. ncbi Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials
    Nilesh Chande
    Division of Gastroenterology, London Health Sciences Centre, The University of Western Ontario, South Street Hospital, 375 South St, London, Ontario, Canada
    Am J Gastroenterol 104:235-41; quiz 234, 242. 2009
    ..To conduct a systematic review to determine effective treatments for patients with collagenous colitis or lymphocytic colitis, the two subtypes of microscopic colitis...
  53. pmc Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
    M J Vaquerizo
    Merck Sharp and Dohme, c Josefa Valcarcel 38, 28027 Madrid, Spain
    Thorax 58:204-10. 2003
    ..A 16 week multicentre, randomised, double blind, controlled study was undertaken to study the efficacy of adding oral montelukast, a leukotriene receptor antagonist, to a constant dose of inhaled budesonide.
  54. ncbi A novel method for assessing dissolution of aerosol inhaler products
    Neal M Davies
    Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, P O Box 646534, Pullman, WA 99164 6534, USA
    Int J Pharm 255:175-87. 2003
    ..b>Budesonide (BD), fluticasone propionate (FP) and triamcinolone acetonide (TA) have high hepatic first-pass inactivation of ..
  55. ncbi Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
    B J Lipworth
    Department of Clinical Pharmacology and Therapeutics and Respiratory Medicine, Ninewells Hospital and Medical School, University of Dundee, Scotland
    Arch Intern Med 159:941-55. 1999
    ..To appraise the data on systemic adverse effects of inhaled corticosteroids...
  56. pmc Daily or intermittent budesonide in preschool children with recurrent wheezing
    Robert S Zeiger
    Department of Allergy, Kaiser Permanente Southern California, San Diego, CA 92111, USA
    N Engl J Med 365:1990-2001. 2011
    ..We compared daily therapy with intermittent therapy...
  57. ncbi Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus
    C L Skevaki
    Second Department of Pediatrics, Allergy Research Center, University of Athens, Athens, Greece
    Clin Exp Allergy 39:1700-10. 2009
    ..b>Budesonide (BUD) and formoterol (FORM) synergize in controlling asthma and COPD exacerbations; however, their effects on ..
  58. ncbi Systematic review and meta-analysis of budesonide/formoterol in a single inhaler
    Steven J Edwards
    Outcomes Research, AstraZeneca UK Ltd, Luton, Bedfordshire, UK
    Curr Med Res Opin 23:1809-20. 2007
    To compare the effectiveness of budesonide/formoterol using fixed dosing (BUD/FORM) with inhaled corticosteroid (ICS) alone or alternative ICS and long-acting beta(2)-agonist (LABA) regimens for adults with moderate/severe asthma.
  59. ncbi Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial
    Donald P Tashkin
    Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, California, USA
    Drugs 68:1975-2000. 2008
    ..b>Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD.
  60. ncbi Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group
    A E Tattersfield
    Division of Respiratory Medicine, Nottingham University, Nottingham, and National Heart and Lung Institute, Imperial College, London, United Kingdom
    Am J Respir Crit Care Med 160:594-9. 1999
    ..severe exacerbations that occurred during a 12-mo parallel group study (FACET) in which low and high doses of budesonide with and without formoterol were compared in patients with asthma...
  61. ncbi Modulation by phenethyl isothiocyanate and budesonide of molecular and histopathologic alterations induced by environmental cigarette smoke in mice
    Francesco D'Agostini
    Department of Health Sciences, University of Genoa, Genoa, Italy
    Cancer Prev Res (Phila) 2:546-56. 2009
    ..In the present study, we evaluated the protective effects of the glucocorticoid budesonide and of the dietary agent phenethyl isothiocyanate in mice exposed to ECS for 9 months followed by 2 months of ..
  62. ncbi Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials
    Malcolm R Sears
    Firestone Institute for Respiratory Health, St Joseph s Healthcare and McMaster University, 50 Charlton Ave East, Hamilton, Ontario, Canada L8N 4A6
    Respir Med 103:1960-8. 2009
    ..This study examined the safety of the inhaled corticosteroid (ICS)/LABA combination budesonide/formoterol dry powder inhaler used as maintenance and reliever therapy versus combination treatments based on ..
  63. ncbi Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial
    O K Bonderup
    Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 1, Randers, Denmark
    Gut 58:68-72. 2009
    To evaluate the efficacy and safety of long-term budesonide therapy for the maintenance of clinical remission in patients with collagenous colitis.
  64. ncbi Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial
    Stephan Miehlke
    Medical Department I, Technical University Hospital, Dresden, Germany
    Gastroenterology 135:1510-6. 2008
    Oral budesonide effectively induces clinical remission in patients with collagenous colitis, a debilitating illness characterized by chronic watery/loose diarrhea, but there is a high rate of relapse after treatment cessation.
  65. ncbi Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis
    Alex Straumann
    Department of Gastroenterology, University Hospital Basel, Basel, Switzerland
    Gastroenterology 139:1526-37, 1537.e1. 2010
    ..Topical corticosteroids are effective in pediatric patients with EoE, but no controlled studies of corticosteroids have been reported in adult patients...
  66. ncbi Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study
    Stephan Miehlke
    Medical Department I, Technical University Hospital, Dresden, Germany
    Gastroenterology 136:2092-100. 2009
    b>Budesonide is effective in treating collagenous colitis, but no treatment is established for lymphocytic colitis...
  67. ncbi The use of inhaled formoterol in the treatment of asthma
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
    Ann Allergy Asthma Immunol 97:24-33. 2006
    ..To discuss the clinical efficacy and safety of formoterol when used to relieve symptoms of asthma and prevent exercise-induced bronchoconstriction (EIB)...
  68. ncbi Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma
    R Buhl
    Pulmonary Department, Mainz University Hospital, Mainz, Germany
    Curr Med Res Opin 23:1867-78. 2007
    ..Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults ..
  69. ncbi Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid
    A Laitinen
    Department of Anatomy, University of Helsinki, Finland
    Am J Respir Crit Care Med 156:951-8. 1997
    ..In patients with birch-pollen-sensitive asthma during the birch-pollen season, inhaled corticosteroid treatment, budesonide 400 micrograms twice daily, decreased tenascin immunoreactivity, in comparison with effects of placebo (p = 0...
  70. ncbi Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial
    Stephan Miehlke
    Medical Department I, Technical University Hospital, Dresden, Germany
    Gastroenterology 123:978-84. 2002
    ..We investigated the effect of budesonide on symptoms and histology in patients with collagenous colitis in a randomized, double-blind, placebo-controlled ..
  71. ncbi Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up
    Filip Baert
    Imelda Hospital Bonheiden, Belgium
    Gastroenterology 122:20-5. 2002
    ..Several treatment options have been suggested, but no controlled data are available. We conducted a placebo-controlled trial to show the clinical and histologic effects of budesonide in CC.
  72. pmc Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada
    Thorax 65:747-52. 2010
    The use of a combination inhaler containing budesonide and formoterol as both maintenance and quick relief therapy (SMART) has been recommended as an improved method of using inhaled corticosteroid/long-acting beta agonist (ICS/LABA) ..
  73. ncbi Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids
    Josephine de Kluijver
    Department of Pulmonology, Lung Function Laboratory, C2 P 62 Leiden University Medical Center, PO Box 9600, NL 2300 RC Leiden, The Netherlands
    Am J Respir Crit Care Med 166:294-300. 2002
    ..They were treated with 400 micro g budesonide once daily (n = 13) or placebo (n = 13) from Days -3 to 19...
  74. ncbi Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects
    John D Brannan
    Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Respirology 7:37-44. 2002
    ..The aim of the study was to investigate whether treatment using inhaled corticosteroids decreases airway responsiveness to inhaled mannitol in asthmatic subjects...
  75. ncbi A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma
    A M Wilson
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
    Clin Exp Allergy 31:616-24. 2001
    ..OBJECTIVE: To compare oral montelukast with inhaled plus intranasal budesonide in patients with seasonal allergic rhinitis and asthma...
  76. ncbi Placebo-controlled study of inhaled budesonide on indices of airway inflammation in bronchoalveolar lavage fluid and bronchial biopsies in cross-country skiers
    M Sue-Chu
    Department of Lung Medicine, University Hospital, Trondheim, Norway
    Respiration 67:417-25. 2000
    ..Asthma-like symptoms, methacholine hyperresponsiveness, use of inhaled steroids, airway inflammation, and increased tenascin expression in the reticular basement membrane have been reported in competitive cross-country skiers...
  77. ncbi Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients
    Valerie J Lund
    Royal National Throat, Nose and Ear Hospital, London, United Kingdom
    Rhinology 42:57-62. 2004
    This study evaluated the efficacy and tolerability of budesonide in an aqueous nasal spray (BANS) in patients with chronic rhinosinusitis...
  78. ncbi Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma
    J H Vermeulen
    Dorp Street 20, Panorama 7500, Cape Town, South Africa
    Respir Med 101:2182-91. 2007
    The aim of the study was to investigate the efficacy and safety of ciclesonide compared with budesonide in adolescents with severe asthma.
  79. ncbi Production and characterization of a budesonide nanosuspension for pulmonary administration
    Claudia Jacobs
    Department of Pharmaceutics, Biopharmaceutics and Biotechnology, Free University of Berlin, Germany
    Pharm Res 19:189-94. 2002
    This study describes the production of a budesonide nanosuspension by high-pressure homogenization for pulmonary delivery from 40 mL up to 300 mL. The aim was to obtain a nanosuspension that can be nebulized and is also long-term stable.
  80. ncbi Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial
    Johanna C Escher
    Department of Paediatric Gastroenterology and Nutrition, Emma Children s Hospital Academic Medical Centre, Amsterdam, The Netherlands
    Eur J Gastroenterol Hepatol 16:47-54. 2004
    b>Budesonide is a corticosteroid with low systemic bioavailability because of its high first-pass metabolism in the liver...
  81. ncbi Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature
    A Sidney Barritt
    Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599 7080, USA
    Inflamm Bowel Dis 14:1695-700. 2008
    ..b>Budesonide, a luminally active steroid with low systemic absorption, is an established therapeutic agent for IBD that ..
  82. ncbi Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients
    Stephen P Peters
    Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Allergy Asthma Proc 29:499-516. 2008
    ..The purpose of this study was to examine the long-term safety of budesonide/formoterol pressurized metered-dose inhaler (pMDI)...
  83. ncbi Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation
    P Santus
    Respiratory Medicine Unit, San Paolo Hospital, University of Milan, Milan, Italy
    Respir Med 100:1277-81. 2006
    ..changes in the degree of pulmonary hyperinflation after acute administration of tiotropium 18 microg or budesonide/formoterol 320/9 microg...
  84. ncbi Detection of budesonide in human urine after inhalation by liquid chromatography-mass spectrometry
    K Deventer
    Doping control laboratory DoCoLab, Ghent University, UGent, Technologiepark 30B, B 9052 Zwijnaarde, Belgium
    J Pharm Biomed Anal 42:474-9. 2006
    b>Budesonide, a corticosteroid frequently used in the treatment of asthma, is most often administered via inhalation. Its use in sports is allowed when medically necessary...
  85. ncbi 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 5 7, 92224 Amberg, Germany
    J Crohns Colitis 5:129-38. 2011
    b>Budesonide may be an effective therapy for mild-to-moderately active ulcerative colitis (UC). This study aimed to demonstrate non-inferiority for oral 9mg budesonide once daily (OD) versus 3g mesalazine granules OD.
  86. ncbi Five-day course of budesonide inhalation suspension is as effective as oral prednisolone in the treatment of mild to severe acute asthma exacerbations in adults
    Chih Feng Chian
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan
    Pulm Pharmacol Ther 24:256-60. 2011
    Limited evidence is available on the use of budesonide inhalation suspension (BIS) for the treatment of mild to severe acute asthma exacerbations (AAE) in adults in an inpatient setting...
  87. ncbi Cooperative inhibitory effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium
    Sofia Persdotter
    AstraZeneca R and D Lund, Lund, Sweden
    Int Arch Allergy Immunol 143:201-10. 2007
    ..To address this, we studied the effects of a LABA, formoterol (FORM), and a GC, budesonide (BUD), alone and in combination, on bronchial epithelial cell-mediated eosinophil superoxide production in vitro.
  88. ncbi Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats
    Fatemeh Ahmadi
    Isfahan University of Medical Sciences, Isfahan, Iran
    Drug Deliv 18:122-30. 2011
    b>Budesonide is an anti-inflammatory drug of choice for treatment of ulcerative colitis which affects the rectum and a part of or the entire colon...
  89. ncbi Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process
    Nagesh Bandi
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198 6025, USA
    Eur J Pharm Sci 23:159-68. 2004
    The purpose of this study was to determine whether budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes could be formed using a supercritical fluid (SCF) process...
  90. ncbi A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma
    B Stallberg
    Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology, Uppsala University, Science Park, Uppsala, Sweden
    Respir Med 102:1360-70. 2008
    ..To evaluate direct asthma-related costs in Swedish primary care in a real-life setting...
  91. ncbi A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain
    Santiago Quirce
    Department of Allergy, Hospital La Paz, IdiPAZ, Madrid, Spain
    J Asthma 48:839-47. 2011
    To study the effectiveness and safety in a real-life setting of budesonide/formoterol (Symbicort) Maintenance And Reliever Therapy® (Symbicort SMART®), a simplified management approach with one inhaler, compared with conventional best ..
  92. ncbi Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093 0956, USA
    Gastroenterology 143:1218-26.e1-2. 2012
    b>Budesonide is a corticosteroid with minimal systemic corticosteroid activity due to first-pass hepatic metabolism...
  93. ncbi Effects of intranasal budesonide on symptoms, quality of life, and performance in elite athletes with allergic rhinoconjunctivitis
    Constance H Katelaris
    Institute of Immunology and Allergy Research, Westmead Hospital, Sydney, Australia
    Clin J Sport Med 12:296-300. 2002
    To assess change in symptoms, quality of life (QOL), and performance ability before, during, and after treatment with budesonide in a group of Olympic and Paralympic athletes with seasonal allergic rhinoconjunctivitis (SAR/C).
  94. pmc A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management
    R Louis
    Pneumology, CHU Sart Tilman, Liege, Belgium
    Int J Clin Pract 63:1479-88. 2009
    To study the effectiveness and safety of budesonide/formoterol (Symbicort) Maintenance And Reliever Therapy (Symbicort SMART, AstraZeneca, Södertalje, Sweden), a simplified management approach with one inhaler compared with conventional ..
  95. ncbi Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma
    L Rosenhall
    Lung and Allergy Clinic, Department of Pulmonary Medicine, Huddinge University Hospital, Stockholm, Sweden
    Int J Clin Pract 56:427-33. 2002
    The aim of this study was to compare the safety and efficacy of budesonide/formoterol 160/4.5 microg, two inhalations twice daily, with that of the mono-products administered at the same daily doses via separate inhalers...
  96. ncbi Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment
    Andreas Münch
    Department of Gastroenterology and Hepatology, Linkopings University, Sweden
    Am J Gastroenterol 104:679-85. 2009
    ..Our aim was to investigate the mucosal barrier to nonpathogenic bacteria in collagenous colitis...
  97. ncbi Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management
    Melissa Roberts
    Lovelace Clinic Foundation, Albuquerque, NM, USA
    J Med Econ 14:769-76. 2011
    To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of ..
  98. ncbi The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients
    Andrew M Wilson
    Asthma and Allergy Research Group, Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
    Eur J Clin Pharmacol 58:643-7. 2003
    ..The aim was to a assess whether skin vasoconstrictor assay might predict airway and systemic tissue responsiveness to inhaled budesonide in patients with asthma.
  99. ncbi Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis
    M Simonoska Crcarevska
    Institute of Pharmaceutical Technology, Faculty of Pharmacy, Ss Cyril and Methodius University, Skopje, Macedonia
    J Drug Target 17:788-802. 2009
    ..delivery system for inflammatory bowel diseases, chitosan-Ca-alginate microparticles efficiently loaded with budesonide (BDS), were designed using one-step spray-drying process...
  100. ncbi Eosinophils and eosinophilic cationic protein in induced sputum and blood: effects of budesonide and terbutaline treatment
    Ruth E Aldridge
    Canterbury Respiratory Research Unit, Christchurch School of Medicine, University of Otago, Christchurch Hospital, Christchurch, New Zealand
    Ann Allergy Asthma Immunol 89:492-7. 2002
    ..Eosinophilic cationic protein (ECP) levels in sputum and blood correlate with clinical severity, and serial measurements of ECP have been proposed as a suitable candidate...
  101. ncbi Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa
    Maja Simonoska Crcarevska
    Institute of Pharmaceutical Technology, Ss Cyril and Methodius University, Skopje, Macedonia
    Eur J Pharm Biopharm 68:565-78. 2008
    ..process uncoated and Eudragit S 100 coated chitosan-Ca-alginate microparticles efficiently loaded with budesonide (BDS), with bioadhesive and controlled release properties in GIT, were prepared...

Research Grants63

  1. New drug VS-110 for treating inflammatory bowel diseases
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2013
    ..Currently drugs for anti-inflammatory diseases in the GI tract such as mesalamine (Asacol, Lialda, Pentasa) and budesonide achieved US$2.9 billion in annual worldwide sales in 2011...
  2. Heart Rate Variability Biofeedback: Its Role in Asthma Therapeutics
    Paul M Lehrer; Fiscal Year: 2013
    ..In an exploratory analysis, we also will estimate its proportional effect compared with a recommended dose of budesonide. To best observe the effects of HRV-BF on airways biology we will study steroid-naove patients with mild to ..
  3. PHARMACOGENOMICS OF INHALED CORTICOSTEROIDS TO REDUCE COPD EXACERBATIONS
    Craig P Hersh; Fiscal Year: 2013
    ..We propose to test this hypothesis in a clinical trial of ICS (budesonide, Pulmicort) or ICS/long acting beta-agonist combination (budesonide/ formoterol, Symbicort) in subjects with ..
  4. Transcleral Therapeutics in Diabetic Retinopathy
    Uday B Kompella; Fiscal Year: 2013
    ..the principles learned from celecoxib prodrugs will be extrapolated to three other model lipophilic drugs, budesonide, ruboxistaurin, and nimesulide. These drugs are of potential therapeutic value in treating diabetic retinopathy...
  5. Collaborative Clinical Research on Hepatotoxicity
    Naga P Chalasani; Fiscal Year: 2013
    ..this unmet therapeutic need, we propose to conduct a randomized, double-blind, placebo-controlled pilot study of budesonide in individuals with well characterized hepatocellular DILI meeting predefined eligibility criteria...
  6. Efficacy of Liposomal Budesonide in Experimental Asthma
    KAMESWARI KONDURI; Fiscal Year: 2004
    ..We propose to investigate the hypothesis that when budesonide, a frequently prescribed inhaled steroid, is encapsulated into sterically-stabilized "stealth" liposomes, it ..
  7. Chemoprevention of Early Pulmonary Lesions in Mice
    ALVIN MALKINSON; Fiscal Year: 2004
    ..b>Budesonide, a synthetic glucocorticoid, and three other anti-inflammatory drugs, each with a unique mechanism of action, ..
  8. Molecular Pathogenesis of Cystic Fibrosis Liver Disease
    Martin Carey; Fiscal Year: 2007
    ..normalizing the lumenal pH using amiloride, a carbonic anhydrase agonist, or by upregulating ASBT activity with budesonide. The molecular insights from these hypothesis-driven specific aims should provide data, molecular understanding ..
  9. Selenium Prevention of Tobacco Smoke-Induced Lung Cancer
    Teresa Fan; Fiscal Year: 2005
    ..whether a synergism exists between Se and other chemopreventive agents such as the glucocorticoid hormone budesonide and retinoid isotretinoin in TS induction of lung cancers...
  10. Chemoprevention in Mice after Tobacco Smoke Exposure
    Hanspeter Witschi; Fiscal Year: 2004
    ..examine whether the topical administration to the tissues of the respiratory tract of other suppressing agents (budesonide- epigallocatechin gallate (EGCG), isotretinoin, or lovastatin) may increase their efficacy while at the same ..
  11. EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS
    Lee Wattenberg; Fiscal Year: 1999
    ..Determine the maximum tolerated dose for budesonide and phenethylisothiocyanate (PEITC) given by aerosol...
  12. Adherence & Treatment Outcome in Adolescents in CAMPCS
    Bruce Bender; Fiscal Year: 2003
    ..Recently analyzed data from the Childhood Asthma Management Program (CAMP) has revealed that average budesonide adherence was 77 percent in the first year but dropped to 55 percent in year four of this multicenter pediatric ..
  13. EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MOD
    Lee Wattenberg; Fiscal Year: 2000
    ..Recently the aerosolized administration of budesonide has been shown to markedly inhibit B[a]P induced adenoma formation in lungs of the Strain A mouse...
  14. EFFICACY OF CHEMOPREVENTIVE AGENTS IN ANIMAL MODELS
    Lee Wattenberg; Fiscal Year: 1999
    ..Recently the aerosolized administration of budesonide has been shown to markedly inhibit B[a]P induced adenoma formation in lungs of the Strain A mouse...
  15. EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS
    Lee Wattenberg; Fiscal Year: 2000
    ..Recently the aerosolized administration of budesonide has been shown to markedly inhibit B[a]P induced adenoma formation in lungs of the Strain A mouse (Wattenberg et ..
  16. Childhood Asthma Research and Education Network: Denver Site
    Stanley Szefler; Fiscal Year: 2008
    ..End of abstract.) [unreadable] [unreadable]..
  17. INFLAMMATION & CORTICOSTEROID RESPONSES IN SEVERE ASTHMA
    KIAN CHUNG; Fiscal Year: 2005
    ..The molecular mechanisms underlying loss of CR will be examined. These studies should lead to more effective therapies for chronic severe asthma. ..
  18. ASTHMA AND INTERVENTIONS IN THE EMERGENCY DEPARTMENT
    Robert Strunk; Fiscal Year: 2002
    ..The intent to treat model will be used, as primary outcome can be obtained after consent even if not contact cannot be made at 2 week and 6 month phone calls. ..
  19. CARE Network--St. Louis Center
    Robert Strunk; Fiscal Year: 2008
    ..End of abstract.) [unreadable] [unreadable]..
  20. Dendritic Cell Vaccination During Lymphoid Reconstitution
    Jeffrey Weber; Fiscal Year: 2008
    ..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
  21. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  22. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  23. CTLA-4 Inhibition and Autoimmunity in Melanoma
    Jeffrey Weber; Fiscal Year: 2008
    ..abstract_text> ..
  24. IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA
    Jeffrey Weber; Fiscal Year: 2003
    ....
  25. Severe Asthma From Respiratory Infections
    William W Busse; Fiscal Year: 2010
    ..These studies will provide new insights into the mechanisms of asthma, particularly severe disease, and possibilities of new approaches to treatment. ..
  26. HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA
    Jeffrey Weber; Fiscal Year: 2003
    ..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
  27. MECHANISMS OF RHINOVIRUS INDUCED ASTHMA
    William Busse; Fiscal Year: 2002
    ..The proposed studies will provide new evidence as the mechanisms by which RV-infected epithelial cells cause granulocytic bronchial inflammation and asthma exacerbations. ..
  28. SCLERODERMA LUNG STUDY
    Donald Tashkin; Fiscal Year: 2003
    ..abstract_text> ..
  29. IL-12 as an Adjuvant for a Melanoma Peptide Vaccine
    Jeffrey Weber; Fiscal Year: 2003
    ..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
  30. Role of eosinophils in intestinal epithelial dysfunction
    Glenn Furuta; Fiscal Year: 2009
    ..Long-term goals of these studies are the identification of specific diagnostic tests for EOGs and the development of novel eosinophil specific treatments. ..
  31. Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children
    Carlos Camargo; Fiscal Year: 2008
    ..The proposed study is cost-effective, as it makes use of an existing cohort, and it will provide information that could have direct clinical application to reduce risk of asthma. [unreadable] [unreadable] [unreadable] [unreadable]..
  32. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2007
    ..therapy using patient adjusted doses of an inhaled corticosteroid/long acting beta-agonist combination (budesonide 160 mu g/formoterol 4...
  33. Innovative Investigations and Therapies for Asthma
    Richard Martin; Fiscal Year: 2007
    ..The ability to predict who will and will not respond to corticosteroids and additive therapy will greatly improve our ability to treat asthma effectively. ..
  34. Prospective Study of Diet, Physical Activity, BMI and Risk of Pulmonary Embolism
    Carlos Camargo; Fiscal Year: 2008
    ..We believe that quantifying these modifiable risk factors will lead to public health interventions that decrease the incidence of pulmonary embolism in the elderly population. [unreadable] [unreadable] [unreadable]..
  35. Genotype-Phenotype Interactions in Severe Asthma
    EUGENE ROLAND BLEECKER; Fiscal Year: 2010
    ..We feel strongly that collaborative research is necessary to meet the goals of this RFA and is crucial to genetic studies. We will continue to participate as an active member of SARP II. ..
  36. CARE Network-UCSD Clinical Center
    Robert Zeiger; Fiscal Year: 2008
    ..abstract_text> ..
  37. Dysbiosis in Inflammatory Bowel Disease
    Ece Mutlu; Fiscal Year: 2008
    ..ALH may enable a real-time survey of microfloral changes for the first time in medicine and may provide the first evidence linking IBD with specific microbial patterns. [unreadable] [unreadable] [unreadable]..
  38. CARCINOGENIC CYCLIC NITROSAMINE DNA ADDUCTS
    Stephen S Hecht; Fiscal Year: 2010
    ..The proposed research is significant because of the known human exposure to these carcinogens through the diet, tobacco products, and endogenous formation. ..
  39. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2008
    ..abstract_text> ..
  40. Lung Cancer Chemoprevention: Isothiocyanates, inositol
    Stephen Hecht; Fiscal Year: 2008
    ..abstract_text> ..
  41. Dietary Treatment of Crohn's Disease
    Ece Mutlu; Fiscal Year: 2007
    ..Significance. This study could provide information to suggest diet as a safe therapy for IBD and lay the groundwork for more definitive, randomized, controlled trials. ..
  42. Genetic studies in difficult to treat asthma: TENOR
    Eugene Bleecker; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  43. Chemoprevention of Tobacco Related Cancer in Animals
    Michael Pereira; Fiscal Year: 2004
    ..carcinogens including cigarette smoke has ceased the animals will be administered the chemo-preventive agents: budesonide and the farnesyl transferase inhibitor, R115777 in the lung studies and budesonide, ketoprofen and sulindac in ..
  44. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2003
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  45. ASTHMA CHRONOBIOLOGY: CENTRAL AND LUNG INTERACTIONS
    Richard Martin; Fiscal Year: 2003
    ....
  46. METABOLISM OF CARCINOGENIC TOBACCO SPECIFIC NITROSAMINES
    Stephen Hecht; Fiscal Year: 2003
    ..abstract_text> ..
  47. Protection from Fas-mediated apoptosis in the gut
    Maria Abreu; Fiscal Year: 2002
    ..The support from this R03 will permit me to successfully compete for an R01 and make the transition to an independent investigator. ..
  48. DIET AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Carlos Camargo; Fiscal Year: 2002
    ..The proposed study is cost-effective, as it makes use of an existing cohort, and it will provide information that could have direct clinical application to reduce risk of COPD. ..
  49. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Richard Martin; Fiscal Year: 2002
    ....
  50. NATURAL AND INDUCED IMMUNITY AGAINST HELICOBACTER PYLORI
    Pierre Michetti; Fiscal Year: 2001
    ..felis infection and during mucosal immunization in both mice and humans. These studies may also contribute to the development of effective vaccination strategies against other enteric pathogens. ..
  51. ASSESSMENT MODE AND VALIDITY OF SELF-REPORTS IN CHILDREN
    Bruce Bender; Fiscal Year: 2004
    ..Results from this investigation are expected to have immediate and direct implication for clinical research in asthma and with other chronic conditions. ..
  52. ROLE OF CD40-CD40 LIGAND IN PRIMARY BILIARY CIRRHOSIS
    MARLYN MAYO; Fiscal Year: 2003
    ..These studies will provide insight into the role of T cells in the pathogenesis of PBC and provide information useful in developing new treatment modalities. ..
  53. In Vitro Cancer Prevention Biomarker Development
    Eugene Elmore; Fiscal Year: 2004
    ..Using cluster analysis, we will determine the global gene expression changes induced by each agent. The strength of the proposed approach lies in the high quality data that has already determined from the HEC Assay. ..
  54. Models and technologies for defining phenotype
    Eugene Bleecker; Fiscal Year: 2006
    ..A heavy emphasis will be placed on discussing, demonstrating, and where feasible performing approaches and techniques useful for characterization of "phenotype" ..
  55. Role of TLR4 in Acute and Chronic Murine Colitis
    Maria Abreu; Fiscal Year: 2006
    ..We will use the support from this R21 to generate robust animal models that establish the requirement for TLR4 in the initiation and perpetuation of intestinal inflammation. ..
  56. IMMUNE MECHANISMS OF MIDDLE EAR DISEASE
    David Skoner; Fiscal Year: 2006
    ..The primary hypothesis is that cytokine genotype is predictive of illness expression and of OM incidence during a documented RSV infection in young children. ..
  57. Tobacco Carcinogenesis
    Stephen Hecht; Fiscal Year: 2005
    ..Steven Tannenbaum (MIT), Dr. Jack Henningfield (Johns Hopkins and Pinney Associates), Drs. Jeffrey Seeman and Anthony Tricker (Philip Morris), and Dr. John Lauterbach (an independent consultant, formerly with Brown and Williamson). ..
  58. Subconjunctival Route to Prolong Corticosteroid Delivery
    Uday Kompella; Fiscal Year: 2005
    ..study proposes subconjunctivally injectable biodegradable nano- and micro-particles to sustain the delivery of budesonide, a corticosteroid, to the posterior segment of the eye for a few months...
  59. Molecular Characterization of the SLC19A2 Promoter
    JACK REIDLING; Fiscal Year: 2005
    ..Nothing is known about possible regulation of the thiamine uptake process during development and whether this includes promoter regulation. These issues will be addressed in this proposal. ..
  60. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  61. 1Treatment of Cholestatic Pruritus With Sertraline
    MARLYN MAYO; Fiscal Year: 2004
    ..These studies will serve as pilot trials. The results of this proposed project will be used to design a larger controlled trial that could be proposed for funding through an R01 mechanism. ..
  62. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2001
    ....